How mutant IDH affects bile duct cancer
Official title: Functions of mutant IDH in cholangiocarcinoma
Funded at Massachusetts General Hospital · NIH-10932410 · Data updated 2026-11-12
This study is looking at how a specific mutation in a gene called IDH1 affects bile duct cancer and helps cancer cells hide from the immune system, with the hope of finding better ways to treat this cancer by combining current therapies with new immune treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 20, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $620,855 |
| NIH project number | 5R01CA280085-02 |
| Project ID | NIH-10932410 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with cholangiocarcinoma, particularly those with IDH1 mutations.
✕Less likely to help
Patients without cholangiocarcinoma or those with other types of cancer may not benefit from this research.
What this research studies
This research investigates the role of mutant isocitrate dehydrogenase 1 (IDH1) in cholangiocarcinoma, a severe form of bile duct cancer. It focuses on how these mutations produce a substance that alters cancer cell behavior, allowing them to evade the immune system. By using advanced mouse models and patient samples, the research aims to understand the mechanisms behind this immune evasion and how it can be reversed to improve treatment outcomes. The ultimate goal is to enhance the effectiveness of existing therapies by combining them with immune checkpoint inhibitors.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for cholangiocarcinoma by improving the immune response against the cancer.
How similar studies have gone: Other research has shown promising results in targeting similar metabolic pathways in cancer, indicating potential for success in this approach.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: El-Bardeesy, Nabeel — Massachusetts General Hospital
- Study coordinator: El-Bardeesy, Nabeel
Related research
Other NIH-funded projects on the same topics.
-
A new mouse model to study intrahepatic cholangiocarcinoma and its immunotherapy
A new mouse model helps researchers understand intrahepatic cholangiocarcinoma and test immune-based treatments to improve outcomes.
-
Radiation plus a patient’s own immune cells to boost cholangiocarcinoma treatment
This project tests a therapy that combines precise radiation and the patient’s own dendritic cells with immune drugs to help fight intrahepatic cholangiocarcinoma in people who cannot have surgery.
-
Worldwide genetics of bile duct (cholangiocarcinoma)
Researchers are looking for genetic patterns that raise the risk of bile duct cancer in people from diverse regions worldwide.
-
MKK4 and Liver Regeneration after Major Liver Surgery
A study at Mayo Clinic will test a new drug, HRX215, to help people regrow liver tissue after major liver surgery for cancer.
-
New mouse model to improve immune therapy for intrahepatic bile duct (cholangiocarcinoma) cancer
This project builds a new mouse model to help make immune-based treatments work better for people with intrahepatic cholangiocarcinoma, a type of bile duct liver cancer.
-
Mutant IDH in bile duct cancer and its impact on immune response
A patient-facing look at how mutations in IDH1 drive bile duct cancer and how targeting this mutation could help immune cells fight the tumor.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.